Illinois is currently home to 2639 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
NCT05714514
Recruiting
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to enable kidney transplantation in clinical study ConfIdeS (20-HMedIdeS-17, NCT04935177).
Gender:
ALL
Ages:
All
Trial Updated:
06/03/2025
Locations: Northwestern University, Dept. General Surgery, Div. Transplantation, Chicago, Illinois
Conditions: Kidney Transplantation in Highly Sensitized Patients
Register for Updates
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451
Recruiting
The purpose of this trial is: 1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 years of age suffering from chronic spontaneous urticaria inadequately controlled by H1-antihistamines 2. to collect long-term efficacy, safety and tolerability data on remibrutinib in adolescents after having completed 24 weeks of treatment 3. to collect safety data in this population for up to three years after the last dose of study treatment
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
06/03/2025
Locations: Endeavor Health, Glenview, Illinois
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349
Recruiting
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/03/2025
Locations: Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois
Conditions: Primary Immune Thrombocytopenia (ITP)
Register for Updates
Father Inclusive Prenatal Care Study
NCT05652387
Recruiting
Young families need additional institutional support to help them meet the challenges of parenthood. Prenatal clinics are well situated to address some of their needs by expanding services to include fathers. The Father Inclusive Prenatal Care (FIPC) model is designed to prepare young men for the challenges of parenting by supporting the development of their relationship skills as part of routine prenatal healthcare. This approach involves assessing expectant fathers and mothers with a "parent p... Read More
Gender:
ALL
Ages:
Between 17 years and 29 years
Trial Updated:
06/03/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Antenatal Care, Pregnancy Related, Parent-Child Relations, Parenting, Education, Counseling
Register for Updates
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114
Recruiting
The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
06/03/2025
Locations: Robert A Hozman MD SC, Skokie, Illinois
Conditions: Systemic Lupus Erythematosus
Register for Updates
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749
Recruiting
The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of standard-of-care (SoC) treatment in participants with active systemic lupus erythematosus (SLE).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
06/03/2025
Locations: Willow Rheumatology Wellness, Willowbrook, Illinois
Conditions: Systemic Lupus Erythematosus
Register for Updates
The Reducing REVISITS Study: A Cluster RCT
NCT05568043
Recruiting
This type II hybrid effectiveness-implementation trial will concurrently study the comparative effectiveness of virtual vs. in-person COPD care transition programs implemented via virtual mentored implementation approaches with and without co-design methods. The investigators will enroll up to 24 randomized sites (with a goal minimum of 16 sites) to: * Deliver the COPD programs implemented via mentored support in collaboration with SHM Center for Quality Improvement. * Compare the effectivenes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: COPD, COPD Exacerbation Acute
Register for Updates
OssDsign® Spine Registry Study ("Propel")
NCT05329129
Recruiting
The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
06/03/2025
Locations: Carle Foundation Hospital, NeuroScience Institute, Urbana, Illinois
Conditions: Degenerative Disc Disease, Spinal Stenosis
Register for Updates
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
NCT05251259
Recruiting
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/03/2025
Locations: Research Site, Chicago, Illinois
Conditions: Asthma
Register for Updates
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05169515
Recruiting
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: The University of Chicago, Chicago, Illinois
Conditions: Non-Hodgkin Lymphoma
Register for Updates
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195
Recruiting
This is an open-label, multi-center, roll-over study to evaluate the long term safety of ribociclib in combination with other drugs in participants who are participating in a Novartis sponsored global study, that has fulfilled requirements for its primary objective(s), and who in the opinion of the Investigator, would benefit from continued treatment.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/03/2025
Locations: Duly Health and Care, Plainfield, Illinois
Conditions: Metastatic Breast Cancer
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Relapsing Multiple Sclerosis
Register for Updates